For example, HER2-E tumors that became Luminal A at day 14 in the PAMELA trial7 had a 20% pCR rate upon completion of the neoadjuvant treatment compared to 55.8% in those HER2-E tumors that became normal-like, a biomarker of tumor responsiveness and stromal contamination. The gene discussed is ERBB2; the disease is neoplasm.